58-WEEK OPEN-LABEL TRIAL OF TAVAPADON IN PARKINSONS DISEASE (TEMPO-4 TRIAL)

Age
40 years - 80 years
Gender
All
participants needed
800
Location
1

Brief description of study

The research study is being conducted to study of an investigational drug (referred to as “study drug” in this document) called CVL-751 (also known as Tavapadon) as a possible treatment for Parkinson’s disease. An investigational drug is one that has not been approved by the United States (US) Food and Drug Administration (FDA).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Parkinsons Disease
  • Age: 40 years - 80 years
  • Gender: All

Previous TEMPO-1 trial participants and diagnosed with Parkinson’s Disease

Updated on 04 Aug 2024. Study ID: 849393
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research